Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Gu érin for the treatment of upper tract carcinoma in situ

CONCLUSION: Endoluminal Gem/Doce and BCG have similar oncological outcomes and major adverse event rates in the treatment of UT-CIS. Further prospective evaluation is warranted.PMID:38609747 | DOI:10.1016/j.urolonc.2024.03.012

Source: Urologic Oncology - April 12, 2024 Category: Urology & Nephrology Authors: Ian M McElree Sarah L Mott Helen Y Hougen Vignesh T Packiam Michael A O'Donnell Ryan L Steinberg Source Type: research